Protocol for high-throughput cloning, expression, purification, and evaluation of bispecific antibodies

Danqing Li; Alexander C Partin; Liangjun Zhao; Irwin Chen; Mark L Michaels; Zhulun Wang; Fernando Garces; Danyang Gong; Timothy P Riley

doi:10.1016/j.xpro.2022.101428

Protocol for high-throughput cloning, expression, purification, and evaluation of bispecific antibodies

STAR Protoc. 2022 May 27;3(2):101428. doi: 10.1016/j.xpro.2022.101428. eCollection 2022 Jun 17.

Authors

Danqing Li¹, Alexander C Partin¹, Liangjun Zhao¹, Irwin Chen², Mark L Michaels¹, Zhulun Wang¹, Fernando Garces¹, Danyang Gong¹, Timothy P Riley¹

Affiliations

¹ Department of Therapeutics Discovery, Amgen Research, Amgen Inc., Thousand Oaks, CA 91320, USA.
² Department of Therapeutics Discovery, Amgen Research, Amgen Inc., San Francisco, CA 94080, USA.

Abstract

Bispecific antibodies are a powerful new class of therapeutics, but their development often requires enormous amounts of time and resources. Here, we describe a high-throughput protocol for cloning, expressing, purifying, and evaluating bispecific antibodies. This protocol enables the rapid screening of large panels of bispecific molecules to identify top candidates for further development. For complete details on the use and execution of this protocol, please refer to Estes et al. (2021).

Keywords: Antibody; Biotechnology and bioengineering; High Throughput Screening; Protein Biochemistry; Protein expression and purification.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Antibodies, Bispecific* / therapeutic use
Cloning, Molecular

Substances

Antibodies, Bispecific